Physician profile
Ethan E Ittner
NPI 1083908248
$5,477.94
in general payments reported to CMS, 2019-2025
27 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $436 · 2021: $108 · 2022: $710 · 2023: $985 · 2024: $1,239 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,477.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.69 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $501.00 | 2020-2025 | Caplyta |
| Bausch Health US, LLC | $472.33 | 2019-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $425.54 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $401.46 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Allergan, INC. | $359.99 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $316.79 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $306.77 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Idorsia Pharmaceuticals US INC | $242.79 | 2022-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $234.58 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $223.04 | 2023-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $217.17 | 2022-2025 | Loreev Xr |
| Corium, LLC | $213.12 | 2022-2024 | Azstarys |
| Tris Pharma INC | $167.93 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $147.36 | 2019-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $107.66 | 2019-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $103.20 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $88.41 | 2022-2025 | Qelbree |
| Lundbeck LLC | $85.34 | 2019-2024 | Rexulti |
| Indivior INC. | $59.25 | 2019-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $49.39 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $41.37 | 2020 | |
| Collegium Pharmaceutical, INC. | $36.61 | 2025 | Jornay Pm |
| Alkermes, INC. | $30.67 | 2020-2022 | |
| Eisai INC. | $24.15 | 2020 | |
| Boston Scientific Corporation | $19.66 | 2023 | |
| Braeburn INC. | $17.67 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Ittner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.